Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBCANZ)

• Drug Name: SB-237376 Drug Info
• Synonyms: SB-237376; UNII-JED8M29NSU; JED8M29NSU; CHEMBL184461; SB-237376 free base; SCHEMBL6737235; XEAKAKKNLOUHDV-UHFFFAOYSA-N; BDBM50151854; n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide; N-{3-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-propyl}-4-nitro-benzamide; Benzamide, N-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-4-nitro-

Indication

Disease Entry	ICD 11	Status	REF
Arrhythmia	BC9Z	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 9845214
  CAS Number: CAS 179258-59-4
  TTD Drug ID: DMBCANZ

Molecule-Related Drug Atlas

Drug(s) Targeting Calcium channel unspecific (CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicardipine	DMCDYW7	High blood pressure	BA00	Approved	[2]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[3]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[4]
Felodipine	DMOSW35	Hypertension	BA00-BA04	Approved	[5]
Nimodipine	DMQ0RKZ	Cerebral vasospasm	BA85.Z	Approved	[6]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[7]
Isradipine	DMA5XGH	Hypertension	BA00-BA04	Approved	[7]
DIPROTEVERINE HYDROCHLORIDE	DMG8U6M	Angina pectoris	BA40	Phase 3	[8]
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[9]
HBI-3000	DM74ZKN	Heart arrhythmia	BC65	Phase 2	[10]

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[7]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[7]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[11]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[7]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[12]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[7]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[7]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[13]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[7]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Modulator	[1]
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Modulator	[1]

References

• [1] Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
• [2] Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
• [3] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [4] RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
• [5] Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
• [6] Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
• [11] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.